Final survival analysis and predictors of treatment discontinuation in patients aged ≥ 80 years receiving adjuvant uracil–tegafur and leucovorin for stage III colorectal cancer: The prospective phase II HiSCO-03 trial

Background In the HiSCO-03 trial of adjuvant uracil–tegafur and leucovorin in patients aged ≥ 80 years with stage III colorectal cancer, the treatment completion rate was lower than expected. This final analysis evaluated long-term outcomes and risk factors for treatment discontinuation. Methods Of 69 enrolled patients, 65 were included in the survival analysis. In exploratory analyses, skeletal muscle mass was measured on preoperative computed tomography at the third lumbar vertebra, and risk factors for discontinuation due to adverse events or patient refusal were analyzed using logistic regression in 45 patients, excluding those who discontinued treatment because of recurrence. Results The 3-year disease-free survival rate was 70.6%, and the 5-year overall, recurrence-free, and disease-free survival rates were 75.9%, 64.5%, and 61.4%, respectively. Of the 45 patients, 30 completed and 15 discontinued treatment. In multivariable analysis, female sex (odds ratio 7.75, 95% confidence interval 1.68–56.59) and low skeletal muscle mass (odds ratio 9.69, 95% confidence interval 1.84–78.11) were independent risk factors for discontinuation. Survival did not differ between patients who completed and those who discontinued treatment. Conclusions In patients aged ≥ 80 years with stage III colorectal cancer, adjuvant uracil–tegafur and leucovorin achieved a 3-year disease-free survival rate comparable to those reported in younger patients. Low skeletal muscle mass and female sex were associated with treatment discontinuation. These factors may help identify, before treatment, patients who are likely to tolerate adjuvant chemotherapy and those who need early supportive care. Trial registration jRCTs061180087 (registered 22 March 2019 retrospectively registered).

Authors

Institutions

Publication Details

Journal
Research Square
Published
2026-11-18
DOI
https://doi.org/10.21203/rs.3.rs-11635534/v1
Primary Topic
Colorectal Cancer Treatments and Studies
Type
preprint
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
NOV
preprint

Final survival analysis and predictors of treatment discontinuation in patients aged ≥ 80 years receiving adjuvant uracil–tegafur and leucovorin for stage III colorectal cancer: The prospective phase II HiSCO-03 trial

Yuji Takakura, Mamoru Oeda, Toshiyuki Moriuchi, Yusuke Sumi et al.
Research Square
Colorectal Cancer Treatments and Studies
preprint

Final survival analysis and predictors of treatment discontinuation in patients aged ≥ 80 years receiving adjuvant uracil–tegafur and leucovorin for stage III colorectal cancer: The prospective phase II HiSCO-03 trial

Yuji Takakura, Mamoru Oeda, Toshiyuki Moriuchi, Yusuke Sumi, Daisuke Sumitani, Kouki Imaoka, Masashi Miguchi, Shintaro Akabane, Tomoaki Bekki, Hideki Ohdan, Hiroyuki Sawada, Shoichiro Mukai, Shinya Kodama, Manabu Shimomura, Haruki Sada, satoshi ikeda, Hironori Kobayashi, Masahiko Fujimori
preprint en

Abstract

Background In the HiSCO-03 trial of adjuvant uracil–tegafur and leucovorin in patients aged ≥ 80 years with stage III colorectal cancer, the treatment completion rate was lower than expected. This final analysis evaluated long-term outcomes and risk factors for treatment discontinuation. Methods Of 69 enrolled patients, 65 were included in the survival analysis. In exploratory analyses, skeletal muscle mass was measured on preoperative computed tomography at the third lumbar vertebra, and risk factors for discontinuation due to adverse events or patient refusal were analyzed using logistic regression in 45 patients, excluding those who discontinued treatment because of recurrence. Results The 3-year disease-free survival rate was 70.6%, and the 5-year overall, recurrence-free, and disease-free survival rates were 75.9%, 64.5%, and 61.4%, respectively. Of the 45 patients, 30 completed and 15 discontinued treatment. In multivariable analysis, female sex (odds ratio 7.75, 95% confidence interval 1.68–56.59) and low skeletal muscle mass (odds ratio 9.69, 95% confidence interval 1.84–78.11) were independent risk factors for discontinuation. Survival did not differ between patients who completed and those who discontinued treatment. Conclusions In patients aged ≥ 80 years with stage III colorectal cancer, adjuvant uracil–tegafur and leucovorin achieved a 3-year disease-free survival rate comparable to those reported in younger patients. Low skeletal muscle mass and female sex were associated with treatment discontinuation. These factors may help identify, before treatment, patients who are likely to tolerate adjuvant chemotherapy and those who need early supportive care. Trial registration jRCTs061180087 (registered 22 March 2019 retrospectively registered).

Research Square
Hiroshima University (JP), Hiroshima City Asa Citizens Hospital (JP), Hiroshima Prefectural Hospital (JP), Higashihiroshima Medical Center (JP), Chugoku Rosai Hospital (JP), National Hospital Organization (JP), Kure Medical Center (JP), Onomichi General Hospital (JP), Yoshida Hospital (JP), National Hospital Organization Hiroshima-Nishi Medical Center (JP), Hiroshima City Hiroshima Citizens Hospital (JP), Hiroshima Prefectural Hospital Organization (JP), Chubu Electric Power (Japan) (JP)
Good health and well-being
Colorectal Cancer Treatments and Studies
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.

Laika access coming soon